Comparative Pharmacology
Head-to-head clinical analysis: ANNOVERA versus KURVELO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ANNOVERA versus KURVELO.
ANNOVERA vs KURVELO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination hormonal contraceptive containing segesterone acetate, a progestin, and ethinyl estradiol, an estrogen. Segesterone acetate suppresses gonadotropin release, preventing ovulation; ethinyl estradiol contributes to contraceptive efficacy by stabilizing the endometrium and inhibiting gonadotropin secretion.
KURVELO (trofinetide) is a synthetic analog of the N-terminal tripeptide of insulin-like growth factor 1 (IGF-1). It is thought to reduce neuroinflammation and normalize synaptic function by modulating the activity of microglia and astrocytes, and by enhancing the phosphatidylinositol-3-kinase (PI3K)/Akt signaling pathway.
One vaginal ring inserted and left in place for 3 weeks, followed by a 1-week ring-free interval. Each ring releases ethinyl estradiol 0.024 mg/day and segesterone acetate 0.15 mg/day over 21 days.
100 mg orally once daily
None Documented
None Documented
Terminal half-life of etonogestrel (ENG): ~25 hours; ethinylestradiol (EE): ~12 hours; steady-state achieved after 7-14 days.
Terminal elimination half-life is 12-15 hours; requires dose adjustment in renal impairment.
Renal: ~60% as metabolites; fecal: ~35% as metabolites; biliary: minor.
Primarily renal excretion (70-80% as unchanged drug), with 10-15% biliary/fecal elimination.
Category C
Category C
Contraceptive
Contraceptive